COVID-19 Drug Candidates - Sortable

 

Click on the column heading to arrange the table in ascending order (or descending order on a second click) of the column heading.  A click on the # column or company column will return the order to the original order.  The table is currently numbered according to alphabeitcal order of the companies.  For other compilations, please visit the sites at the bottom of the table (especially # 10).  For many other sites (primaily chemistry related) as well as pre-show Powerpoint and Trivia presentations, please visit http://murov.info. Sites developed and uploaded by Steven Murov, Professor Emeritus of Chemistry, Modesto Junior College http://murov.info/resume.htm .

 

#
Drug
Company
function
Test Stage, clinical trial
links
Sample Reference
links
Notes

 

1
 Kaletra Abbvie   Phase 3   lop lopi HIV      
2
Favipiravir AdooQ Bioscience treatment Phase 3  favip favipi anitviral    
3
nitric oxide Air Liquide treatment Phase 2 no
4
AT-100 (rhSP-D) Airway Therapeutics treatment AT-1
5
AJ Vaccines vaccine aj
6
NP-120 (Ifenprodil) Algernon Pharm. treatment np
7
AdCOVID Altimmune vaccine adc nasal spray
8
APN01  APEIRON Biologics treatment Phase 1 apn        
9
LUNAR-COV19 Arcturus Therapeutics vaccine Preclinical Arc. engineered RNA
10
danoprevir, ritonavir Ascletis Pharma treatment Phase 1   da dan.  med HIV, hepatitis C
11
Ciclesonide AstraZeneca treatment Phase 2  cicle cicles asthma care    
12
BPI-002 BeyondSpring treatment   bp        
13
Galidesivir (BCX4430) Biocryst treatment gal bcx        
14
BNT162 BioNTech, Pfizer,
 CureVac
vaccine Preclinical Bio RNA based
15
BXT-25 BIOXYTRAN treatment bxt
16
CM4620-IE CalciMedica Inc. treatment Phase 2 cm4        
17
Ad5-nCoV CanSino Biologics vaccine Phase 1   ad CSB modified virus
18
  CEL-SCI treatment   cel immunotherapy      
19
Lopinavir, Ritonavir
(LOPIMUNE)
Cipla   Phase 3   lop sci HIV
20
S-Trimer Clover Biopharm. vaccine (subunit)   s-t        
21
  Codagenix vaccine   cod        
22
leronlimab (PRO 140) CytoDyn treatment Phase 2, ler ler respiratory      
23
baricitinib
Eli Lilly
treatment
respiratory
24
Emergent BioSolutions treatment eme
25
EIDD-2801 Emory Univ. Bio treatment   cen  dru antiviral      
26
Fusogenix Entos Pharm. vaccine fus DNA based
27
  Generex vaccine   gene peptide vaccines      
28
remdesivir Gilead treatment Phase 3   re rem.  sci  cen Ebola antiviral
29
gp96 Heat Biologics vaccine   hb, gp        
30
TJM2 I-Mab Biopharma treatment tj cytokine storm
31
TJ003234 I-Mab Biopharma treatment Phase 1,2  tj      
32
  ImmunoPrecise Antibodies vaccine   imm

PolyTope mAb Therapy

     
33
Brilacidin Innovation Pharm. treatment   bri developed for oral issues      
34
INO-4800
Inovio Pharm.
vaccine
DNA based
35
Integral Molecular vaccine im
36
Prezista J&J treatment
       
37
darunavir/cobicistat
(PREZCOBIX)
Janssen Pharm.   Phase 3  pre prez HIV
38
AmnioBoost Lattice Biologics treatment phase 1 amn stem cell technology      
39
  LineaRx,
  Takis
 Biotech
vaccine   lin DNA based      
40
OT-101 Mateon Therapeutics treatment phase 3 ma        
41
  Medicago vaccine   me1 plant based      
42
IBV MIGAL Research Inst. vaccine   ibv        
43
mRNA-1273 Moderna vaccine Phase 1   mr mRNA  mod
44
hydroxychloroquine Mylan treatment clinical    hyd hy malaria approved
45
NanoViricide treatment nan nanotech
46
Ruxolitinib Novartis treatment Phase 2   rux ruxo respiratory
complications
   
47
NVX-CoV2373 Novavax vaccine Phase 1 nvx MERS vaccine      
48
ChAdOx1 nCoV-19 Oxford vaccine Phase 1, ch cha adenovirus vaccine vector      
49
OYA1 OyaGen treatment   oya        
50
Azithromycin Pfizer treatment Phase 3 azith      
51
Tranexamic acid

Cyklokapron
Pfizer
LGM Pharma
treatment Phase 1, 2   tran tran blod clotting    
52
  Predictive Oncology vaccine pre AI Platform      
53
REGN3048, REGN3051
Regeneron Pharm. treatment Preclinical   re Reg. virus mimic
54
Kevzara

(Sarilumab)
Regeneron, Sanofi treatment Phase 2,3kev
ke arthritiis approved
55
actemra
Roche treatment Phase 3   act
roc arthritis appoved  
56
Tocilizumab Roche treatment Phase 2   tocil tociliz  
57
Gimsilumab Roivant Sciences treatment   gim antibody        
58
Nitazoxanide

(Alinia)
ROMARK Phase 4 nita antiviral
59
Sanofi
vaccine
Preclinical
RNA modification
60
Losartan Sharp Health Care treatment Preclinical  losa respiratory failure    
61
Emapalumab, Anakinra Sobi treatment Phase 2, 3   ema emap respiratory
complications
62
SNG001 Synairgen Research treatment sn syn inhaler
63
Takeda treatment Preclinical Tak blood plasma        
64
TZLS-501 Tiziana Life Sciences treatment tzl  
65
Angiotensin 1-7 Tocris Bio. treatment Phase 2, 3  angio a17 respiratory
complication
s
66
TNX-1800 Tonix Pharm. vaccine   tnx        
67
Favilavir Toyama Chemical treatment   fav approved in China for C-19        
68
cGMP Vaxart vaccine   cgmp        
69
VIR-7831, VIR-7832 Vir Biotechnology treatment Preclinical Vir antibodies        
70
Zydus Cadila vaccine zyd  
71
chloroquine
Zydus Cadila,

    Ipca Labs
treatment  clinical  chl sci malaria, arthritis approved        
72
AM580
  treatment am580 antiviral        
73
ribavirin    
74
Vitamin D   treatment test vd
75
Vitamin C
(ascorbic acid)
  treatment test vitc    
76
                 
77
78
79
                 
80
                 
 
           

The compilation above was extracted primarily from the web sites 2,3,5 below.  For up-to-date information on the status of testing of any drug, please see reference 1.   During the development of this site, other sites that have complimentary and supplementary information were found (see especially references 9, 10) but it was decided to go ahead and finish this site.  The developer of this site does have a chemistry background, he is not a medical doctor, pharacologist or biochemist and has no expertise in the field of disease treatment or prevention.  Any information obtained from this site should be checked and double checked by doing appropriate literature and Internet research on the topic. The links provided for each drug represent a very small sample of available Internet sites with information on the drug. The site is intended only as a quick reference and perhaps as a consideration of possible drugs for compassionate use. Please send comments and suggestions to murovs@yosemite.edu .

 

 

1.  https://www.clinicaltrials.gov/ct2/results?cond=COVID-19

 

2.  https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/

3.  https://www.statnews.com/2020/03/19/an-updated-guide-to-the-coronavirus-drugs-and-vaccines-in-development/

4.  https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments   

5.  https://www.marketwatch.com/story/these-nine-companies-are-working-on-coronavirus-treatments-or-vaccines-heres-where-things-stand-2020-03-06    look for most current version

 

6. https://www.genengnews.com/news/coronavirus-treatment-could-lie-in-existing-drugs/ &  list of possible antivirals

7.  https://www.nbcnews.com/health/health-news/here-are-some-existing-drugs-may-be-repurposed-treat-coronavirus-n1162021a>

8.  https://www.eurekalert.org/pub_releases/2020-03/g-af9032520.php

9.  https://www.bioworld.com/COVID19products

 

10. a.  https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf

     b.  https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker-4-1-WEB.pdf

 

11 https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1

 

12.  https://www.evaluate.com/vantage/articles/analysis/vantage-views/long-path-effective-coronavirus-vaccine#

 

13.  https://www.researchandmarkets.com/reports/5008860/2020-covid-19-drug-pipeline-report-current?utm_source=MC&utm_medium=Email&utm_code=mzrzfbv27&utm_campaign=1386618+-+2020+COVID+19+Drug+Pipeline+Report-+Current+Status%2c+Phase%2c+Companies%2c+Pre-Clinical+And+Clinical+Drugs&utm_exec=jape284mtd

https://www.clinicaltrials.gov/ct2/results?pg=1&load=cart&id=NCT04333550+OR+NCT04336904+OR+NCT04324489+OR+NCT04333420+OR+NCT04324996+OR+NCT04340232+OR+NCT04317092+OR+NCT04330586+OR+NCT04315298+OR+NCT04304313+OR+NCT04340544+OR+NCT04341675+OR+NCT04333628+OR+NCT04307693+OR+NCT04323631+OR+NCT04337216+OR+NCT04292899+OR+NCT04331470+OR+NCT04320615+OR+NCT04305106+OR+NCT04308317+OR+NCT04342221+OR+NCT04332107+OR+NCT04334044+OR+NCT04332913+OR+NCT04286503+OR+NCT04333472+OR+NCT04331665+OR+NCT04328272+OR+NCT04335071+OR+NCT04323514+OR+NCT04338698+OR+NCT04310228+OR+NCT04335552+OR+NCT04324021+OR+NCT04334967+OR+NCT04275414+OR+NCT04321174+OR+NCT04293887+OR+NCT04327388+OR+NCT04325893+OR+NCT04337918+OR+NCT04291729+OR+NCT04288713+OR+NCT04306393+OR+NCT04322123+OR+NCT04264533+OR+NCT04315480

 

https://www.clinicaltrials.gov/ct2/results?pg=1&load=cart&id=NCT04333550+OR+NCT04336904+OR+NCT04324489+OR+NCT04335123+OR+NCT04340232+OR+NCT04321993+OR+NCT04329832+OR+NCT04317092+OR+NCT04330586+OR+NCT04331899+OR+NCT04315298+OR+NCT04304313+OR+NCT04326920+OR+NCT04340544+OR+NCT04334512+OR+NCT04341675+OR+NCT04330690+OR+NCT04333628+OR+NCT04331795+OR+NCT04307693+OR+NCT04292899+OR+NCT04329572+OR+NCT04292730+OR+NCT04305106+OR+NCT04320615+OR+NCT04308317+OR+NCT04273529+OR+NCT04338074+OR+NCT04329650+OR+NCT04280588+OR+NCT04335201+OR+NCT04337359+OR+NCT04332107+OR+NCT04328441+OR+NCT04334044+OR+NCT04341116+OR+NCT04334005+OR+NCT04286503+OR+NCT04333472+OR+NCT04338828+OR+NCT04273321+OR+NCT04339426+OR+NCT04331665+OR+NCT04338958+OR+NCT04338126+OR+NCT04335071+OR+NCT04323514+OR+NCT04326790+OR+NCT04334265+OR+NCT04333589+OR+NCT04328480+OR+NCT04303507+OR+NCT04328012+OR+NCT04324021+OR+NCT04298060+OR+NCT04332991+OR+NCT04332666+OR+NCT04252664+OR+NCT04312009+OR+NCT04311177+OR+NCT04275414+OR+NCT04341935+OR+NCT04323761+OR+NCT04332042+OR+NCT04305457+OR+NCT04324463+OR+NCT04320277+OR+NCT04327401+OR+NCT04280705+OR+NCT04321174+OR+NCT04312243+OR+NCT04333654+OR+NCT04341493+OR+NCT04327388+OR+NCT04324073+OR+NCT04326426+OR+NCT04288713+OR+NCT04322344+OR+NCT04322773+OR+NCT04340557+OR+NCT04315480+OR+NCT04275245+OR+NCT04328467+OR+NCT04308668



hit counter restarted 7/5/20 counter free

 

unique visitors restarted 7/5/20  counter free